Redeye is encouraged by Nekkar’s acquisition of Globetech which was announced this morning.
Redeye presents its preview of Sedana Medical’s Q2 2024 report, due on July 23.
Redeye konstaterar att Donanemab, under det kommersiella namnet Kisunla, som väntat fått ett fullt g...
Profitability below expectations Duell’s Q3 net sales came in at EUR 37.
Q2 preview: EBITA growth of 16% y-o-y In Q2, we expect easy growth comps to result in a sequential a...
Railcare säkrar tillgång till framtidssäkrade lok genom innovativ affär.
Windon Energy Group (”Windon” eller ”bolaget”) meddelade den 2 juli år 2024 att bolaget har erhållit...
Redeye updates its estimates ahead of the Q2 report following today’s announced 5G order.
Redeye comments on EG7’s acquisition of S6 which is the developer and publisher of the online multip...
Redeye offers a preview of Doro's Q2 results set to be released on July 17th.
Redeye is only making minor changes to our estimates and valuation following the full-year report.
Redeye provides an update as we resume our coverage after CLS’ rights issue.
Nettoomsättningen uppgick till 43,7 MSEK (44,4) i det fjärde kvartalet (februari-april) i Purefuns b...
Our earnings bridge: We expect Q2 Paper EBIT of PLN 38m, down from PLN 94m in Q1'24.
Our earnings bridge We expect Q2 clean EBIT of ~SEK 63m, up from SEK 5m in Q1'24 and SEK 57m in Q2’2...
What to expect in Q2'24 We expect sales of SEK 266m for Q2'24, implying a y-o-y decline of -11%, alo...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 28 juni år 2024 a...
Duell publishes its business review for Q3 (March-May) on Wednesday 3rd of July.
Redeye initiates coverage of Nekkar, an industrial technology group offering ocean-based technologie...
Last week Railcare announced a deal that will secure the supply of locomotives for some of its impor...